Skip to content
Disclosery

Fairmount Funds Management LLC

Follow

13F filer, CIK 1802528, WEST CONSHOHOCKEN, PA

Fairmount Funds Management LLC reported $771,902,136 across 17 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-14. Its ten largest share positions make up 80.5% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-25-078521

Period
2025-06-30
Reported value
$772M
Holdings
17
Top 10 weight
80.5%
New
3
Sold out
1

Part of the filer group Fairmount Funds Management LLC

  • Fairmount Healthcare Fund II L.P.
  • Harwin Peter Evan
  • Kiselak Tomas
How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
JBIOnew+3,220,368$32.2M
CBIOnew+1,387,866$22.4M
KNSAadded+670,591$18.6M
SRRKadded+450,000$15.9M
ELVNadded+508,646$10.2M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
BCAXexited-784,170-$10.2M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0001104659-25-078521, largest first. % of portfolio is the value over $771,902,136, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
APGEAPOGEE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,048,647 shares; 2024Q4: 2,048,647 shares; 2025Q1: 2,048,647 shares; 2025Q2: 2,048,647 shares 2,048,647$89M11.53%0Timeline
AXSMAXSOME THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,360,077 shares; 2024Q4: 1,468,983 shares; 2025Q1: 815,176 shares; 2025Q2: 815,176 shares 815,176$85.1M11.02%0Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,202,798 shares; 2024Q4: 3,202,798 shares; 2025Q1: 3,202,798 shares; 2025Q2: 3,711,444 shares 3,711,444$74.5M9.65%+508,646Timeline
SRRKSCHOLAR ROCK HLDG CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,962,953 shares; 2025Q1: 1,374,031 shares; 2025Q2: 1,824,031 shares 1,824,031$64.6M8.37%+450,000Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,018,101 shares; 2024Q4: 4,018,101 shares; 2025Q1: 4,018,101 shares; 2025Q2: 4,018,101 shares 4,018,101$60.2M7.79%02026-10-07, 13D/A: 10,185,961 shares, 9.99% of the class, 13D/A filed 2026-10-09 Timeline
NUVLNUVALENT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,687,064 shares; 2024Q4: 1,317,664 shares; 2025Q1: 727,563 shares; 2025Q2: 727,563 shares 727,563$55.5M7.19%0Timeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,700,691 shares; 2024Q4: 2,700,691 shares; 2025Q1: 2,700,691 shares; 2025Q2: 2,707,191 shares 2,707,191$50.4M6.53%+6,500Timeline
KNSAKINIKSA PHARMACEUTICALS INTLQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,204,841 shares; 2024Q4: 2,194,341 shares; 2025Q1: 1,102,248 shares; 2025Q2: 1,772,839 shares 1,772,839$49.1M6.36%+670,591Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,445,813 shares; 2024Q4: 3,445,813 shares; 2025Q1: 3,445,813 shares; 2025Q2: 3,459,913 shares 3,459,913$48.4M6.27%+14,100Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,225,641 shares; 2024Q4: 6,225,641 shares; 2025Q1: 6,225,641 shares; 2025Q2: 6,225,641 shares 6,225,641$44.7M5.79%0Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,211,922 shares; 2024Q4: 3,371,922 shares; 2025Q1: 3,371,922 shares; 2025Q2: 3,371,922 shares 3,371,922$37.8M4.9%0Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 3,220,368 shares 3,220,368$32.2M4.17%newTimeline
CBIOCRESCENT BIOPHARMA INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,387,866 shares 1,387,866$22.4M2.9%newTimeline
ASTRIA THERAPEUTICS INCASTRIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,554,129 shares; 2024Q4: 3,554,129 shares; 2025Q1: 3,554,129 shares; 2025Q2: 3,554,129 shares 3,554,129$19.1M2.47%0
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,892,806 shares; 2024Q4: 1,892,806 shares; 2025Q1: 1,892,806 shares; 2025Q2: 1,892,806 shares 1,892,806$18.3M2.38%0Timeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 6,125,000 shares; 2025Q1: 6,125,000 shares; 2025Q2: 6,125,000 shares 6,125,000$11.9M1.55%0Timeline
CTMXCYTOMX THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 3,896,582 shares 3,896,582$8.85M1.15%newTimeline

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
BCAXBICARA THERAPEUTICS INC784,170$10.2Mshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-25-078521 base2025-08-14acceptance time not in the bulk data set